检索结果-南通市图书馆

RANBp9 as potential therapeutic target in non-small cell lung cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Cancer Metastasis and Treatment 2020年第1期6卷 177-187页

作者： Anna Tessari Shimaa H.A.Soliman Arturo Orlacchio Marina Capece Joseph M.Amann Rosa Visone david p.carbone Dario palmieri Vincenzo Coppola Department of Cancer Biology and Genetics College of MedicineThe Ohio State University and Arthur G.James Comprehensive Cancer CenterColumbusOH 43210USA Department of Medicine Dentistry and BiotechnologyG.d’Annunzio University of ChietiChieti 66100Italy Current address:Department of Biochemistry and Molecular Genetics Northwestern University Feinberg School of MedicineChicagoIL 60611USA Division of Medical Oncology Department of Internal MedicineCollege of MedicineThe Ohio State University and Arthur G.James Comprehensive Cancer CenterColumbusOH 43210USA

Non-small cell lung cancer(NSCLC)remains the leading cause of cancer-related deaths in the Western *** progress made with targeted therapies and immune checkpoint inhibitors,the vast majority of patients have to undergo chemotherapy with platinum-based *** increase efficacy and reduce potential side effects,a more comprehensive understanding of the mechanisms of the DNA damage response(DDR)is *** have shown that overexpressby live cell imaging Incuyion of the scaffold protein RAN binding protein 9(RANBp9)is pervasive in *** importantly,patients with higher levels of RANBp9 exhibit a worse outcome from treatment with platinum-based ***,RANBp9 exists as a target and an enabler of the ataxia telangiectasia mutated(ATM)kinase ***,the depletion of RANBp9 in NSCLC cells abates ATM activation and its downstream targets such as pby live cell imaging Incuy53 ***9 knockout cells are more sensitive than controls to the inhibition of the ataxia and telangiectasia-related(ATR)kinase but not to ATM *** absence of RANBp9 renders cells more sensitive to drugs inhibiting the poly(ADp-ribose)-polymerase(pARp)resulting in a“BRCAness-like”*** summary,as a result of increased sensitivity to DNA damaging drugs conferred by its ablation in vitro and in vivo,RANBp9 may be considered as a potential target for the treatment of *** article aims to report the results from past and ongoing investigations focused on the role of RANBp9 in the response to DNA damage,particularly in the context of *** review concludes with future directions and speculative remarks which will need to be addressed in the coming years.

关键词： RANBp9 RANBp10 Scorpins DNA damage DNA repair DNA damage response CTLH complex cisplatin non-small cell lung cancer pARp BRCAness-like phenotype

液体活检在肺癌管理中新技术的发展和临床应用的拓展（英文）

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science Bulletin 2024年第10期 1556-1568页

作者：陈克终何越王文香袁晓秋 david p.carbone 杨帆 Department of Thoracic Surgery Peking University People's Hospital peking University people's Hospital Thoracic Oncology Institute&Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer peking University Health Science Center Thoracic Oncology Center Ohio State University

Lung cancer is an exceedingly malignant tumor reported as having the highest morbidity and mortality of any cancer worldwide, thus posing a great threat to global health. Despite the growing demand for precision medicine, current methods for early clinical detection, treatment and prognosis monitoring in lung cancer are hampered by certain bottlenecks. Studies have found that during the formation and development of a tumor, molecular substances carrying tumor-related genetic information can be released into body fluids. Liquid biopsy(LB), a method for detecting these tumor-related markers in body fluids, maybe a way to make progress in these bottlenecks. In recent years, LB technology has undergone rapid advancements. Therefore, this review will provide information on technical updates to LB and its potential clinical applications, evaluate its effectiveness for specific applications, discuss the existing limitations of LB, and present a look forward to possible future clinical applications. Specifically, this paper will introduce technical updates from the prospectives of engineering breakthroughs in the detection of membrane-based LB biomarkers and other improvements in sequencing technology. Additionally, it will summarize the latest applications of liquid biopsy for the early detection, diagnosis, treatment,and prognosis of lung cancer. We will present the interconnectedness of clinical and laboratory issues and the interplay of technology and application in LB today.

关键词：

A candidate targeting molecule of insulin-like growth factor-Ⅰ receptor for gastrointestinal cancers

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2010年第46期16卷 5779-5789页

作者： Yasushi Adachi Hiroyuki Yamamoto Hirokazu Ohashi Takao Endo david p.carbone Kohzoh Imai Yasuhisa Shinomura First Department of Internal Medicine Sapporo Medical University Department of Internal Medicine Sapporo Shirakabadai Hospital Vanderbilt-Ingram Cancer Center and Departments of Medicine and Cell Biology Vanderbilt University

Advances in molecular research in cancer have brought new therapeutic strategies into clinical *** new group of targets is tyrosine kinase receptors,which can be treated by several strategies,including small molecule tyrosine kinase inhibitors(TKIs) and monoclonal antibodies(mAbs).Aberrant activation of growth factors/receptors and their signal pathways are required for malignant transformation and progression in gastrointestinal(GI) *** concept of targeting specif ic carcinogenic receptors has been validated by successful clinical application of many new *** I insulin-like growth factor(IGF) receptor(IGF-IR) signaling potently stimulates tumor progression and cellular differentiation,and is a promising new molecular target in human *** this review,we focus on this promising therapeutic target,*** IGF/IGF-IR axis is an important modifier of tumor cell proliferation,survival,growth,and treatment sensitivity in many malignant diseases,including human GI *** studies demonstrated that downregulation of IGF-IR signals reversed the neoplastic phenotype and sensitized cells to anticancer *** results were mainly obtained through our strategy of adenoviruses expressing dominant negative IGF-IR(IGF-IR/dn) against gastrointestinal cancers,including esophagus,stomach,colon,and *** also summarize a variety of strategies to interrupt the IGFs/IGF-IR axis and their preclinical *** mAbs and TKIs targeting IGF-IR have entered clinical trials,and early results have suggested that these agents have generally acceptable safety profiles as single *** summarize the advantages and disadvantages of each strategy and discuss the merits/demerits of dual targeting of IGF-IR and other growth factor receptors,including Her2 and the insulin receptor,as well as other alternatives and possible drug ***,IGF-IR might be a candidate for a molecular therapeutic target in human GI carcino

关键词： Dominant negative Gastrointestinal cancer Insulin like growth factor-I receptor Monoclonal anti-body Tyrosine kinase inhibitor

Microphysiological systems for solid tumor immunotherapy:opportunities and challenges

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Microsystems & Nanoengineering 2023年第6期9卷 77-106页

作者： Sara Abizanda-Campo María Virumbrales-Muñoz Mouhita Humayun Ines Marmol david J.Beebe Ignacio Ochoa Sara Oliván Jose M.Ayuso Department of Dermatology University of Wisconsin-MadisonMadisonWIUSA University of Wisconsin carbone Cancer Center MadisonWIUSA Department of Biomedical Engineering University of WisconsinMadisonWIUSA Tissue Microenvironment Lab(TME lab) Aragón Institute of Engineering Research(I3A)University of ZaragozaZaragozaSpain Instituto de Investigación Sanitaria Aragón(IISA) ZaragozaSpain Centro Investigación Biomédica en Red.Bioingeniería Biomateriales y Nanomedicina(CIBER-BBN)ZaragozaSpain Department of Obstetrics and Gynecology University of Wisconsin-MadisonMadisonWIUSA Department of Biological Engineering Massachusetts Institute of Technology CambridgeCambridgeMAUSA Department of pathology&Laboratory Medicine University of WisconsinMadisonWIUSA

Immunotherapy remains more effective for hematologic tumors than for solid *** of the main challenges to immunotherapy of solid tumors is the immunosuppressive microenvironment these tumors generate,which limits the cytotoxic capabilities of immune effector cells(e.g.,cytotoxic T and natural killer cells).This microenvironment is characterized by hypoxia,nutrient starvation,accumulated waste products,and acidic ***-hijacked cells,such as fibroblasts,macrophages,and T regulatory cells,also contribute to this inhospitable microenvironment for immune cells by secreting immunosuppressive cytokines that suppress the antitumor immune response and lead to immune ***,there is a strong interest in developing new drugs and cell formulations that modulate the tumor microenvironment and reduce tumor cell immune *** systems(MpSs)are versatile tools that may accelerate the development and evaluation of these therapies,although specific examples showcasing the potential of MpSs remain *** in microtechnologies have led to the development of sophisticated microfluidic devices used to recapitulate tumor *** resulting models,also known as microphysiological systems(MpSs),are versatile tools with which to decipher the molecular mechanisms driving immune cell antitumor cytotoxicity,immune cell exhaustion,and immune cell exclusion and to evaluate new targeted ***,we review existing microphysiological platforms to study immuno-oncological applications and discuss challenges and opportunities in the field.

关键词： immunotherapy versatile solid

Considerations for determining optimal mouse caging density

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国比较医学杂志 2008年第1期18卷 26-26页

作者： Charmaine Foltz Larry carbone david DeLong Bernard E. Rollin pascalle Van Loo Julia Whitaker Axel Wolff Division of Veterinary Resources National Institutes of Health Bethesda MD. University of California San Francisco San Francisco CA. Veterinary Medical Unit VA Medical Center Minneapolis MN. Colorado State University Fort Collins CO. Utrecht University The Netherlands. Department of pathology and Laboratory Medicine Division of Laboratory Animal Medicine University of North Carolina Chapel Hill NC. Division of Compliance Oversight OLAW National Institutes of Health Bethesda MD. Correspondence should be addressed to Charmaine Foltz DVM

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Urology 2019年第1期6卷 57-64页

作者： Tyler Etheridge Shivashankar Damodaran Adam Schultz Kyle A.Richards Joseph Gawdzik Bing Yang Vincent Cryns david F.Jarrard Department of Urology University of Wisconsin-MadisonMadisonWIUSA Department of Medicine University of Wisconsin-MadisonMadisonWIUSA University of Wisconsin-Madison Carbone Cancer CenterUniversity of Wisconsin-MadisonMadisonWIUSA

Androgen deprivation therapy(ADT)has been the standard of care for the last 75 years in metastatic hormone sensitive prostate cancer(pCa).However,this approach is rarely *** clinical trials have demonstrated that ADT combined with other agents,notably docetaxel and abiraterone,lead to improved *** mechanisms surrounding this improved cancer outcomes are incompletely *** response of cancer cells to ADT includes apoptosis and cell death,but a significant fraction remains *** laboratory has demonstrated both in vitro and in vivo that cellular senescence occurs in a subset of these *** senescence is a phenotype characterized by cell cycle arrest,senescenceassociated b-galactosidase(SA-b-gal),and a hypermetabolic *** features of cellular senescence include growth arrest and immune stimulation,although persistence may release cytokines and growth factors that are *** tumor cells generate a catabolic state with increased glycolysis,protein turnover and other metabolic changes that represent targets for drugs,like metformin,to be applied in a synthetic lethal *** review examines the response to ADT and the putative role of cellular senescence as a biomarker and therapeutic target in this context.

关键词： prostate cancer Cellular senescence Androgen deprivation therapy Combination therapy Synthetic lethal targeting Metformin Statins

performance and calibration of quark/gluon-jet taggers using 140 fb^(-1) of pp collisions at √s=13 TeV with the ATLAS detector

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese physics C 2024年第2期48卷 1-25页

作者： G. Aad B. Abbott K. Abeling N.J. Abicht S.H. Abidi A. Aboulhorma H. Abramowicz H. Abreu Y. Abulaiti B.S. Acharya C. Adam Bourdarios L. Adamczyk S.V. Addepalli M.J. Addison J. Adelman A. Adiguzel T. Adye A.A. Affolder Y. Afik M.N. Agaras J. Agarwala A. Aggarwal C. Agheorghiesei A. Ahmad F. Ahmadov W.S. Ahmed S. Ahuja X. Ai G. Aielli A. Aikot M. Ait Tamlihat B. Aitbenchikh I. Aizenberg M. Akbiyik T.p.A. Åkesson A.V. Akimov D. Akiyama N.N. Akolkar K. Al Khoury G.L. Alberghi J. Albert p. Albicocco G.L. Albouy S. Alderweireldt M. Aleksa I.N. Aleksandrov C. Alexa T. Alexopoulos F. Alfonsi M. Algren M. Alhroob B. Ali H.M.J. Ali S. Ali S.W. Alibocus M. Aliev G. Alimonti W. Alkakhi C. Allaire B.M.M. Allbrooke J.F. Allen C.A. Allendes Flores p.p. Allport A. Aloisio F. Alonso C. Alpigiani M. Alvarez Estevez A. Alvarez Fernandez M. Alves Cardoso M.G. Alviggi M. Aly Y. Amaral Coutinho A. Ambler C. Amelung M. Amerl C.G. Ames D. Amidei S.p. Amor Dos Santos K.R. Amos V. Ananiev C. Anastopoulos T. Andeen J.K. Anders S.Y. Andrean A. Andreazza S. Angelidakis A. Angerami A.V. Anisenkov A. Annovi C. Antel M.T. Anthony E. Antipov M. Antonelli F. Anulli M. Aoki T. Aoki J.A. Aparisi pozo M.A. Aparo L. Aperio Bella C. Appelt A. Apyan N. Aranzabal S.J. Arbiol Val C. Arcangeletti A.T.H. Arce E. Arena J-F. Arguin S. Argyropoulos J.-H. Arling O. Arnaez H. Arnold G. Artoni H. Asada K. Asai S. Asai N.A. Asbah J. Assahsah K. Assamagan R. Astalos S. Atashi R.J. Atkin M. Atkinson H. Atmani p.A. Atmasiddha K. Augsten S. Auricchio A.D. Auriol V.A. Austrup G. Avolio K. Axiotis G. Azuelos D. Babal H. Bachacou K. Bachas A. Bachiu F. Backman A. Badea p. Bagnaia M. Bahmani A.J. Bailey V.R. Bailey J.T. Baines L. Baines O.K. Baker E. Bakos D. Bakshi Gupta V. Balakrishnan R. Balasubramanian E.M. Baldin p. Balek E. Ballabene F. Balli L.M. Baltes W.K. Balunas J. Balz E. Banas M. Bandieramonte A. Bandyopadhyay S. Bansal L. Barak M. Barakat E.L. Barberio D. Barberis M. Barbero M.Z. Barel K.N. Barends T. Barillari M-S. Barisits T. Barklow p. Baron D.A. Baron Mo The ATLAS Collaboration

The identification of jets originating from quarks and gluons,often referred to as quark/gluon tagging,plays an important role in various analyses performed at the Large Hadron Collider,as Standard Model measurements and searches for new particles decaying to quarks often rely on suppressing a large gluon-induced *** paper describes the measurement of the efficiencies of quark/gluon taggers developed within the ATLAS Collaboration,using √s=13 TeV proton–proton collision data with an integrated luminosity of 140 fb^(-1) collected by the ATLAS *** taggers with high performances in rejecting jets from gluon over jets from quarks are studied:one tagger is based on requirements on the number of inner-detector tracks associated with the jet,and the other combines several jet substructure observables using a boosted decision tree.A method is established to determine the quark/gluon fraction in data,by using quark/gluon-enriched subsamples defined by the jet *** in tagging efficiency between data and simulation are provided for jets with transverse momentum between 500 GeV and 2 TeV and for multiple tagger working points.

关键词： ATLAS JET QUARK GLUON TAGGING